Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 8:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Lorcaserin on Cannabis Withdrawal and Self-administration

NCT03253926
Conditions
Cannabis Use
Interventions
Lorcaserin, Placebo, Marijuana
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Obesity
Interventions
Lorcaserin 10 mg BID, Matching Placebo BID
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
3,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Diego, California
Conditions
Obesity
Interventions
lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Willingboro, New Jersey
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of APD356 in the Treatment of Obesity

NCT00116740
Conditions
Obesity
Interventions
APD356
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Lorcaserin for Preventing Weight Gain Among Smokers

NCT02393547
Conditions
Tobacco Use Disorder, Weight Gain
Interventions
Varenicline, Lorcaserin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Mechanisms of Lorcaserin for Smoking Cessation

NCT04396834
Conditions
Tobacco Use Disorder, Smoking Cessation
Interventions
Lorcaserin Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
The Mind Research Network
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Cannabis Use Disorder
Interventions
lorcaserin, Fitbit Charge HR
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Obesity
Interventions
lorcaserin hydrochloride XR, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
16
States / cities
Phoenix, Arizona • Bell Gardens, California • Long Beach, California + 13 more
Conditions
Epilepsies, Myoclonic, Drug Resistant Epilepsy
Interventions
Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years and older
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 14 more
Conditions
Renal Impairment
Interventions
Lorcaserin 10mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Hepatic Impairment
Interventions
Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Cardiovascular Diseases
Interventions
Ziprasidone, Lorcaserin, Placebo Oral Tablet
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Obesity, Weight Loss, Overweight
Interventions
Lorcaserin
Drug
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Conditions
Nicotine Dependence
Interventions
lorcaserin, nicotine patch, placebo lorcaserin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Weight Gain
Interventions
lorcaserin, Intensive dietary counseling
Drug · Behavioral
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Long Beach, California
Conditions
Cocaine-Related Disorders, Opioid-Related Disorders
Interventions
Group A Lorcaserin (10mg), Group A2 Lorcaserin (20 mg), Group B Parallel Placebo, Group B2 Parallel Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 55 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lorcaserin in the Treatment of Cocaine Use Disorder

NCT03007394
Conditions
Cocaine-Related Disorders
Interventions
Lorcaserin, Placebo Oral Capsule
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
272 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 9 more
Conditions
Obesity
Interventions
Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Diego, California
Conditions
Obesity
Interventions
Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
4,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Completed Not applicable Interventional Results available

Lifestyle Modification and Lorcaserin for Weight Loss Maintenance

NCT02388568
Conditions
Obesity
Interventions
Lorcaserin, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Laboratory Screening of Lorcaserin for Alcohol Use Disorder

NCT04396847
Conditions
Alcohol Use Disorder, Tobacco Smoking
Interventions
Lorcaserin Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
The Mind Research Network
Other
Eligibility
21 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Predictors of Lorcaserin-Induced Weight Loss

NCT03353220
Conditions
Overweight and Obesity
Interventions
Belviq, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Addressing Post Cessation Weight Gain

NCT02412631
Conditions
Obesity, Smoking Cessation
Interventions
lorcaserin, Varenicline, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Chronic Weight Management
Interventions
lorcaserin + phentermine placebo, lorcaserin + phentermine-HCl + phentermine placebo, lorcaserin + phentermine-HCl
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Birmingham, Alabama • Chandler, Arizona • La Jolla, California + 10 more